

Year	Date	Presenter	Title	Journal	Year	Vol	Page
2019	4/2	藤岡	Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA	Blood Adv	2018	2	2724-2731
	4/19	長井	Pharmacologic control of CAR-T cell function using dasatinib	Blood Adv	2019	3	711-717
		千綿	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients	Blood	2019	133	1457-1464
	4/16	田口	The genetic basis and cell of origin of mixed phenotype acute leukaemia	Nture	2018	562	373-379
		クリクラ	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study	J Clin Oncol	2019		Epub
	5/7	千綿	Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry	Bone Marrow Transplant	2019		Epub
		澤山	Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia	J Clin Oncol	2019	37	580-588
	5/14	山田	The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation	Hematol Oncol	2018	37	54-61
		宮崎	Managing Clonal Hematopoiesis in Patients With Solid Tumors	J Clin Oncol	2018	37	711
	5/21	クリクラ	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma	J Clin Oncol	2019	37	1188-1199
		桐野	A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma	Biol Blood Marrow T ransplant	2019		Epub
	5/28	児嶋	Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up	J Clin Oncol	2018	36	3315-3325
		安藤	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia.	Cancer Cell	2019	35	369-385
	6/4	新山	A revised international prognostic score system for Waldenström's macroglobulinemia.	Leukemia	2019		Epub
		佐藤	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.	N Engl J Med	2019	22	2104-2155
	6/11	藤岡	Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.	Cancer Discov	2019		Epub
		波多	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.	Nat commun	2019	10(1)	2031
	6/18	クリクラ	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.	Lancet Oncol	2019	20(7)	998-1010
	6/25	坂本	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).	Lancet Haematol	2019	6(3)	e132-e143
		長井	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT.	Nat commun	2019	10(1)	1065